Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of hMG dose on embryo quality in advanced-age women undergoing IVF with PPOS
2025-524761-25-00Phase 4Authorised
- Sponsor
- Fundació Santiago Dexeus Font
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human follicle stimulating hormone and menotropins in female infertility (2 arms), sponsored by Fundació Santiago Dexeus Font. Primary endpoints: Embryo quality comparison between stimulation groups and Fertilization rate (primary). Planned start Jun 2026; status: authorised.
02
Drugs
recombinant human follicle stimulating hormonemenotropins
03
Conditions
female infertility
Beyond the preview
Go deeper on 2025-524761-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524761-25-00.